The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study.
PSP
PSP phenotype
disease burden
mortality
progressive supranuclear palsy
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
11
2021
accepted:
09
06
2022
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Progressive supranuclear palsy (PSP) is a rare, relentlessly progressive, ultimately fatal neurodegenerative brain disease. The objective of this study was to assess the burden of PSP on patients, caregivers, and healthcare systems by PSP phenotype. Data were drawn from the Adelphi PSP Disease Specific Programme™, a cross-sectional study of neurologists and people living with PSP in the United States of America, France, Germany, Italy, Spain, and the United Kingdom. All people living with PSP with a reported phenotype were included. PSP phenotype was reported for 242 patients (mean age: 70.2 years, 58% male): PSP-Richardson's syndrome,
Identifiants
pubmed: 35865639
doi: 10.3389/fneur.2022.821570
pmc: PMC9295700
doi:
Types de publication
Journal Article
Langues
eng
Pagination
821570Informations de copyright
Copyright © 2022 Pillas, Klein, Gasalla, Avbersek, Thompson, Wright, Mellor and Scowcroft.
Déclaration de conflit d'intérêts
DP, AK, TG, AA, AT, and AS were employed by UCB Pharma during the course of this work and may hold/have access to stock options. JW and JM are employees of Adelphi Real World.
Références
Nervenarzt. 2011 Feb;82(2):207-14
pubmed: 20669002
J Neurol. 2021 Mar;268(3):796-809
pubmed: 31321513
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
Neurology. 1998 Jun;50(6):1637-47
pubmed: 9633705
J Geriatr Psychiatry Neurol. 2017 Sep;30(5):267-272
pubmed: 28747135
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
PLoS One. 2011;6(8):e22293
pubmed: 21829612
JAMA Neurol. 2020 Mar 1;77(3):377-387
pubmed: 31860007
Parkinsonism Relat Disord. 2013 Nov;19(11):980-5
pubmed: 23968651
Acta Neuropathol. 2020 Aug;140(2):99-119
pubmed: 32383020
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
J Neurol. 2014 Aug;261(8):1575-83
pubmed: 24888315
Continuum (Minneap Minn). 2013 Oct;19(5 Movement Disorders):1189-212
pubmed: 24092286
Neuroimage Clin. 2020;25:102152
pubmed: 31935638
J Neurol. 2016 Feb;263(2):380-389
pubmed: 26705121
Parkinsonism Relat Disord. 2018 Apr;49:95-99
pubmed: 29336906
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
Neurology. 2015 Aug 4;85(5):404-12
pubmed: 26138942
Front Neurol. 2021 Jul 01;12:694872
pubmed: 34276544
J Mov Disord. 2020 May;13(2):118-126
pubmed: 32241079
Hong Kong Med J. 2019 Dec;25(6):444-452
pubmed: 31796642
Dysphagia. 2020 Aug;35(4):667-676
pubmed: 31676923
Pract Neurol. 2021 Oct;21(5):376-383
pubmed: 34215700
Diagnostics (Basel). 2022 Feb 02;12(2):
pubmed: 35204476
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7319-7324
pubmed: 28655841
J Neurol Sci. 2021 Feb 15;421:117293
pubmed: 33385754
Ann Indian Acad Neurol. 2021 Jan-Feb;24(1):56-62
pubmed: 33911380
J Neurol. 2021 Sep;268(9):3400-3408
pubmed: 33704556
Front Neurol. 2021 Feb 04;12:630153
pubmed: 33613435
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S34-6
pubmed: 26421392
Front Neurol. 2020 Mar 10;11:180
pubmed: 32218768
Parkinsonism Relat Disord. 2019 Dec;69:34-39
pubmed: 31665686